TGFB1 and cervical carcinoma: This is the first report revealing that CA alone and CA co-treated with Met may reverse the mesenchymal phenotype of TGF-β1-treated cervical tumor cells and we believe that the use of the two small molecules may be considered a potential therapeutic approach for metastatic cervical cancer.